Pay in 4 interest-free payments of $6.13 Learn more
Ships within 48 hours · Estimated delivery Oct 12 - Oct 17
Dosage: Direct transition possible from injectable Wegovy
In 2021, semaglutides weight-loss brand Wegovy (weekly injectable) was approved for obesity, followed by tirzepatide (Mounjaro) for diabetes (2022) and Zepbound (tirzepatide for obesity) in late 2023
2017;43(Suppl 1):2S207
January 21, 2025 Maintaining a healthy weight can be frustrating
SEMA: once-weekly subcutaneous semaglutide 2.4 mg
Bradley DP, Kulstad R, Racine N, Shenker Y, Meredith M, Schoeller DA
US$ 25.78
US$ 26.82
US$ 29.47
